WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - ROCHE GS/SWISSCOM N/ABB LTD/ZURICH INS... Stock

Certificat

KJHCDU

CH1129033044

Market Closed - Swiss Exchange 11:20:00 2024-07-02 EDT
68.95 CHF -0.29% Intraday chart for WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - ROCHE GS/SWISSCOM N/ABB LTD/ZURICH INS...
Current month-0.29%
1 month+8.24%
Date Price Change
24-07-02 68.95 -0.29%
24-06-28 69.15 -0.22%
24-06-26 69.3 -0.57%

Delayed Quote Swiss Exchange

Last update July 02, 2024 at 11:20 am

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KJHCDU
ISINCH1129033044
Date issued 2021-09-01
Strike 366.8 CHF
Maturity 2024-09-02 (62 Days)
Parity 0.37 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 95.8 CHF
Lowest since issue 60.35 CHF
Spread 10 CHF
Spread %1.45%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
248.5 CHF
Average target price
278.3 CHF
Spread / Average Target
+11.98%
Consensus
  1. Stock Market
  2. Certificates
  3. KJHCDU Certificat